National Association of Testing Authorities, Australia
Scope of Accreditation
NSW Health Pathology
Site
NSW Health Pathology Royal Prince Alfred Hospital Laboratory
Accreditation No.
2146
Site No.
2139
Date of Accreditation
16 Dec 1986
Address
14 - 96 Missenden Road
Camperdown, NSW 2050
Australia
Contact
Ms Wafa Jeha P: +61 (02) 87385082
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Blue Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Cardiac Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Department of Chemical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Blood | Phosphatidylethanol (PEth) |
| Blood; Plasma; Serum | Ethyleneglycol (monoethylene glycol, MEG); Methanol | |
| Plasma; Serum | Caffeine | |
| Methadone | ||
| Nordothiepin | ||
| Thiocyanate | ||
| Plasma; Serum; Urine | Ethanol | |
| Urine | Methadone metabolites | |
| Diquat; Paraquat | ||
| Amphetamines; Benzodiazepines; Cannabinoids; Cocaine; Opiates | ||
| Chemical pathology - Biochemical genetic services - Amino acid quantitation | Plasma; Serum; Urine | Alanine; Arginine; Asparagine; Aspartic acid; Citrulline; Glutamic acid; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Ornithine; Phenylalanine; Serine; Taurine; Threonine; Tryptophan; Tyrosine; Valine |
| Chemical pathology - Biogenic amines | Urine | Serotonin |
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | Cyclosporin |
| Tacrolimus | ||
| Sirolimus | ||
| Plasma; Serum | Quinine; Thiopentone | |
| Vigabatrin | ||
| Methotrexate | ||
| Ampicillin; Cefazolin; Cefepime; Flucloxacillin; Linezolid; Meropenem; Piperacillin | ||
| Amitriptyline; Clomipramine; Clonazepam; Clozapine; Desipramine; Dothiepin (dosulepin); Doxepin; Fluoxetine; Gabapentin; Imipramine; Mianserin; Norclomipramine; Norclozapine; Nordoxepin; Norfluoxetine; Nortriptyline; Perhexiline; Topiramate | ||
| Lamotrigine | ||
| Amisulpride; Aripiprazole; Dehydro aripiperazole; Fluconazole; Haloperidol; Itraconazole; Norquetiapine; Olanzapine; Paliperidone; Posaconazole; Quetiapine; Risperidone; Voriconazole; Zuclopenthixol | ||
| Amikacin; Carbamazepine; Digoxin; Gentamicin (cidomycin, septopal, genticyn, garamycin); Lithium; Paracetamol (acetaminophen); Phenobarbitone; Phenytoin (dilantin); Salicylate; Theophylline; Tobramycin; Valproate (valproic acid, epilim); Vancomycin | ||
| Plasma; Serum; Urine | Cotinine | |
| Chemical pathology - Detection and/or quantitation of tumour markers | Ascitic fluid; Cyst fluid; Pericardial fluid; Peritoneal dialysis fluid; Peritoneal fluid; Pleural fluid; Synovial fluid | CA125 antigen (CA125); CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA); α-Fetoprotein (AFP) |
| Plasma; Serum | Chromogranin A - Gen II | |
| Human chorionic gonadotropin (hCG) | ||
| Neuron specific enolase (NSE) | ||
| CA125 antigen (CA125); CA15-3 antigen (CA15-3); CA19-9 antigen (CA19-9); CA72-4 antigen (CA72-4); Carcinoembryonic antigen (CEA); Prostate specific antigen (PSA); Prostate specific antigen (PSA) - Free; Thyroglobulin; α-Fetoprotein (AFP) | ||
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Renin |
| Copeptin | ||
| Vasoactive intestinal peptide (VIP) | ||
| Adrenocorticotropic hormone (ACTH) | ||
| Glucagon | ||
| Plasma; Serum | Insulin | |
| Cortisol; Dehydroepiandrosterone sulfate (DHEAS); Follicle stimulating hormone (FSH); Luteinising hormone (LH); Oestradiol; Parathyroid hormone (PTH); Progesterone; Sex hormone binding globulin (SHBG); Testosterone - Free; Testosterone - Total | ||
| Macroprolactin; Prolactin | ||
| C-peptide; Calcitonin; Growth hormone | ||
| Pancreatic polypeptide (PP) | ||
| Gastrin; Gastrin-17 | ||
| Leptin | ||
| Plasma; Serum; Urine | Aldosterone | |
| Saliva | Cortisol | |
| Serum | 17α-Hydroxyprogesterone | |
| Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
| Urine | Cortisol | |
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Glycated haemoglobin (HbA1c) | ||
| Plasma; Serum | Fructosamine | |
| Chemical pathology - Further investigation of cardiac function | Plasma; Serum | N-Terminal-pro b-type natriuretic peptide (NT-proBNP); Troponin T |
| Serum | Creatine kinase (CK) isoenzymes | |
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Plasma; Serum | Apolipoprotein A; Apolipoprotein B; HDL - Quantitation; LDL apolipoprotein B; LDL direct (LDLD); Lipoprotein subclasses; Unesterified cholesterol (UC) lipids; VLDL cholesterol; VLDL triglycerides |
| Serum | Lipoprotein a | |
| Lipoprotein subclasses | ||
| Chemical pathology - Further investigation of renal and/or hepatic function | Plasma; Serum | Alkaline phosphatase (ALP) isoenzymes |
| Lactate dehydrogenase (LDH) isoenzymes | ||
| α1-Antitrypsin | ||
| Caeruloplasmin; Prealbumin | ||
| Plasma; Serum; Urine | Bile acids | |
| Urine | Oxalate | |
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Cerebrospinal fluid (CSF) | Xanthochromia |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Ascitic fluid; Cyst fluid; Drainage fluid; Pericardial fluid; Peritoneal dialysis fluid; Peritoneal fluid; Pleural fluid; Synovial fluid | Albumin; Amylase; Bilirubin - Total; Cholesterol - Total; Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Potassium; Protein - Total; Sodium; Triglycerides; Urate |
| Blood; Plasma; Serum | Butyrylcholinesterase (BChE) | |
| Cerebrospinal fluid (CSF) | Chloride; Glucose; Lactate; Protein - Total | |
| Cerebrospinal fluid (CSF); Serum | Angiotensin converting enzyme (ACE) | |
| Plasma | Ammonia | |
| Plasma; Serum | Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Chloride; Cholesterol - LDL; Cholesterol - Total; Cholinesterase; Creatine kinase; Creatinine; Glucose; High sensitivity C-reactive protein (CRP); Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Soluble transferrin receptor (sTFR); Triglycerides; Urate; Urea; γ-Glutamyltransferase | |
| Bilirubin - Direct | ||
| Plasma; Serum; Urine | Osmolality | |
| Urine | Albumin; Amylase; Calcium - Total; Chloride; Creatinine; Glucose; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea | |
| Microalbumin | ||
| Chemical pathology - Investigation for folate deficiency | Plasma; Serum | Folate |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Plasma; Serum | α-Fetoprotein (AFP) |
| Free β-human chorionic gonadotropin (free β-hCG); Placental growth factor (PGF, PLGF); Pregnancy associated plasma protein A (PAPP-A) | ||
| Serum | FMS-like tyrosine kinase 1 - Soluble / Placental growth factor (PGF, PLGF) ratio | |
| Chemical pathology - Investigation of porphyria | Blood; Plasma | Porphyrins - Total |
| Faeces | Coproporphyrin iii/i isomer ratio; Porphyrin components; Porphyrins - Total | |
| Urine | Porphyrin components; Porphyrins - Total | |
| Porphobilinogen (PBG); δ-Aminolevulinic acid (δ-ALA) | ||
| Chemical pathology - Iron studies | Plasma; Serum | Ferritin |
| Iron; Transferrin | ||
| Chemical pathology - Markers of bone metabolism | Plasma; Serum | Bone-specific alkaline phosphatase - Ostase |
| Urine | Deoxypyridinoline (DPD) | |
| n-Telopeptide (NTx) | ||
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
| Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH | ||
| Chemical pathology - Quantitation of precursor and intermediary metabolites | Plasma; Serum | Homocysteine |
| Free fatty acids - Total; β-Hydroxybutyrate | ||
| Urine | Cystine; Homocysteine | |
| Chemical pathology - Quantitation of vitamin B markers | Plasma; Serum | Holotranscobalamin (active vitamin B12) |
| Chemical pathology - Quantitation of vitamins | Blood | Pyridoxine (vitamin B6, pyridoxal, pyridoxamine); Thiamine (vitamin B1) |
| Riboflavin (vitamin B2) | ||
| Plasma; Serum | Carotenoids | |
| 25-Hydroxyvitamin D | ||
| Ascorbic acid (vitamin C); Retinol (vitamin A); Tocopherol (vitamin E) | ||
| Cobalamin (vitamin B12) | ||
| Urine | Niacin metabolites | |
| Chemical pathology - Tests for thyroid function | Plasma; Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Thyroxine (T4) - Free | ||
| Chemical pathology - Trace element analysis | Blood | Antimony |
| Blood; Liver; Plasma; Urine | Copper | |
| Blood; Other body fluids | Magnesium | |
| Blood; Plasma; Urine | Selenium; Zinc | |
| Blood; Urine | Arsenic; Cadmium; Lead; Manganese; Mercury; Thallium | |
| Manganese | ||
| Liver; Urine | Iron | |
| Plasma | Aluminium | |
| Bromide; Molybdenum | ||
| Plasma; Urine | Cobalt | |
| Chromium | ||
| Urine | Antimony; Iodine; Nickel | |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Plasma | Anti-thyroid stimulation immunoglobulin antibodies (TSI); Thyroid blocking immunoglobulins (TBI) |
| Plasma; Serum | Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | |
| Anti-islet cell antigen 2 antibodies; Anti-islet tyrosine phosphatase2 (IA2) antibodies | ||
| Anti-thyroid stimulating hormone receptor antibodies (TSHRAb) | ||
| Anti-insulin antibodies | ||
| Anti-glutamic acid decarboxylase antibodies (GAD) | ||
| 21-Hydroxylase antibodies (21-OHAA) | ||
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Plasma; Serum | Retinol binding protein |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis of pregnancy | Plasma; Serum | Human chorionic gonadotropin (hCG) |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Urine | pH |
Department of Haematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Haematology - Bone marrow examination | Bone marrow | Examination of aspirated material; Histological examination |
| Haematology - Diagnosis of thalassemia | Blood | Examination of haemoglobin H (HbH); Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation |
| Haematology - Examination of blood films by special staining | Blood | Heinz bodies |
| Malaria | ||
| Bone marrow | Iron | |
| Urine | Haemosiderin | |
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Feto-maternal haemorrhage (FMH) estimation |
| Haematology - Full blood examination | Blood | Differential number; Morphology |
| Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Mean platelet volume (MPV); Platelet count; Red blood cell distribution width (RDW); Red blood cell index or indices; Reticulocytes | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Platelet function (PFA) |
| Platelet aggregation | ||
| Blood; Plasma | Heparin induced thrombotic thrombocytopenia (HITT); Vaccine-induced thrombotic thrombocytopenia (VITT) | |
| Activated protein C (APC) resistance; Anti-Xa - Dabigatran; Anti-thrombin III; Echis test; Factor II; Factor V; Factor VII; Factor X; Lupus anticoagulant; Protein C and protein S; Reptilase time | ||
| Heparin induced thrombotic thrombocytopenia (HITT) | ||
| Von Willebrand collagen binding assay; Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | ||
| Factor VIII | ||
| APTT heparin neutralisation; Activated partial thromboplastin time (APTT); Anti-Xa - Apixaban; Anti-Xa - Dabigatran; Anti-Xa - Fondaparinux; Anti-Xa - Orgaran; Anti-Xa - Rivaroxaban; Anti-Xa activity - Clexane - Low molecular weight heparin; D-dimer; Echis test; Emicizumab levels; Fibrinogen; International normalised ratio (INR); Mixing studies - APTT; Prothrombin time (PT); Prothrombin time (PT) mixing studies; Thrombin time (TT); Tinzaparin anti-XA assays | ||
| Factor IX; Factor IX inhibitor; Factor VIII; Factor VIII inhibitor; Factor XI; Factor XII; Factor XIII; Von Willebrand factor (vWF); Von Willebrand factor (vWF) activity - Ristocetin co-factor assay | ||
| Haematology - Investigation of haemolysis | Blood | Hereditary spherocytosis |
| Plasma | Haemoglobin (Hb) | |
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Blood | Paroxysmal nocturnal haemoglobinuria (PNH) surface markers |
| CD10; CD103; CD117; CD11b; CD11c; CD123; CD13; CD138; CD14; CD15; CD16; CD19; CD1a; CD2; CD20; CD200; CD22; CD23; CD235a; CD24; CD25; CD27; CD28; CD3; CD33; CD34; CD36; CD38; CD4; CD41a; CD43; CD45; CD5; CD56; CD57; CD59; CD61; CD64; CD7; CD71; CD79a; CD79b; CD8; CD81; FMC7; Fluorescein-labelled proaerolysin (FLAER); HLA-DR antigen; Haemoglobin F (HbF); Immunoglobulin M (IgM); Kappa light chains; Lambda light chains; MPO; Minimal residual disease (MRD); Paroxysmal nocturnal haemoglobinuria (PNH) surface markers; T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd); Terminal deoxynucleotidyl transferase (TdT) | ||
| Blood; Bone marrow; Cerebrospinal fluid (CSF); Fresh tissue | Leukaemia screen; Lymphoma screen | |
| Immunopathology - Procedures related to the collection, processing, storage and issue of human haemopoietic progenitor cells | Blood; Bone marrow; Haemopoietic progenitor cells | Enumeration of CD34+ cells |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood | Infectious mononucleosis |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood | Factor V Leiden; Nucleic acid analysis for specific variants; Prothrombin variant |
| Molecular genetics - DNA extraction | Blood; Bone marrow | DNA storage for future analyses; Purified PCR product; Sample assessment and identification; Viable DNA |
| Molecular genetics - DNA sequencing | Blood; Bone marrow | DNA sequence analysis; DNA sequencing reaction purification step; Sequenced DNA; Sequenced DNA utilising massively parallel sequencing technologies |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Blood; Bone marrow | Myeloproliferative leukaemia virus oncogene (MPL); BCR-ABL gene rearrangement; CBFB-MYH11 gene rearrangement; Calreticulin; Essential thrombocythemia (ET); FLT3-ITD (internal tandem duplication) mutation; FLT3-TKD (tyrosine kinase domain) mutation; Isocitrate dehydrogenase IDH1 and IDH2 mutation analysis; JAK2 V617F mutation; JAK2 exon 12 mutation; Leukaemic gene rearrangements; Myeloproliferative disorders; Nucleic acid analysis for specific variants; Nucleophosmin 1 (NPM1) mutation; PML-RARA gene rearrangement; Polycythaemia vera; Primary myelofibrosis; RUNX1/RUNX1T1 gene rearrangement |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood | Quantitation of donor and recipient bone marrow derived cells in a transplant recipient |
| Molecular genetics - Screening for an unknown mutation - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood; Bone marrow | Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative neoplasms |
| Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences; FASTQ files; RNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
Department of Immunohaematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Investigation of haemolysis | Blood | Cold agglutinins |
| Immunohaematology - Blood group antibody detection | Blood; Plasma | Duffy system; Kell system; M and N factors; Other blood group systems; Rh phenotypes |
| Immunohaematology - Blood grouping | Blood; Plasma | ABO; RhD |
| Immunohaematology - Determination of compatibility of blood donor units | Blood; Plasma | Direct antiglobulin test (DAT, direct Coombs test); Electronic crossmatch; Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies; Indirect antiglobulin test (IAT) |
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Antibody elution |
| Blood; Plasma | Other blood group antibodies; Red blood cell phenotyping; Rh | |
| Plasma | Antibody titration | |
| Immunohaematology - Investigation of blood transfusion reactions | Blood; Blood products | Antibodies; Contamination - Microbiological; Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood; Blood products; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood; Blood products; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Issue and release of blood and blood products for transfusion |
Department of Immunology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Further investigation of renal and/or hepatic function | Serum | Haptoglobins |
| Tryptase | ||
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Serum | β2-Microglobulin (B2M) |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Cerebrospinal fluid (CSF) | Albumin |
| Serum | C1 esterase inhibitor | |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Cerebrospinal fluid (CSF) | Anti-neuronal antibodies |
| Serum | Anti-F actin antibodies; Anti-adrenal cortex antibodies; Anti-cardiac antibodies; Anti-endomysial antibodies (EMA); Anti-gastric parietal cell antibodies (GPC/PCA); Anti-glomerular basement membrane antibodies (anti-GBM); Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-neuronal antibodies; Anti-neutrophil cytoplasmic antibodies (ANCA); Anti-nuclear antibodies (ANA); Anti-pemphigoid antibodies; Anti-pemphigus antibodies; Anti-skeletal muscle antibodies; Anti-smooth muscle antibodies (SMA) | |
| Anti-extractable nuclear antigen antibodies (ENA); Anti-ganglioside antibodies; Anti-histone antibodies (AHA); Anti-liver antibodies; Anti-myositis antibodies; Anti-neuronal antibodies; Anti-ribosomal P protein antibodies | ||
| Anti-HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) | ||
| Rheumatoid factor | ||
| Anti-RNA polymerase III antibodies (ARA, RNAP); Anti-cardiolipin IgG antibodies (ACA); Anti-cardiolipin IgM antibodies (ACA); Anti-cyclic citrullinated peptide antibodies (CCP); Anti-deamidated gliadin antibodies; Anti-double stranded DNA antibodies (dsDNA); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase antibodies (tTG) | ||
| Anti-extractable nuclear antigen antibodies (ENA) | ||
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential component testing [purified native and/or recombinant allergens]) | Serum | Ara h2 - Peanut; Omega-5-gliadin - Wheat; Ovomucoid - Egg |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Amoxicillin; Amoxicilloyl group; Ampicilloyl group; Cefaclor; Chlorhexidine; Morphine; Penicilloyl G; Penicilloyl V; Suxamethonium (succinylcholine) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Cat dander; Cow dander; Dog dander; Horse dander |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Chicken; Egg white |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Blue mussel; Codfish; Crab; Lobster; Salmon; Shrimp; Tuna |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fruit and vegetable] allergens) | Serum | Apple; Avocado; Banana; Kiwi; Orange citrus; Strawberry; Tomato |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [meat] allergens) | Serum | Beef; Pork |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Cheese - Cheddar type; Cheese - Mould type; Cow milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [miscellaneous] allergens) | Serum | Baker's yeast |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Barley; Brazil nut; Buck wheat; Cashew nut; Coconut; Corn; Hazelnut; Lupin seed; Macadamia nut; Oat; Peanut; Pecan nut; Pinenut; Pistachio; Rice; Rye; Sesame seed; Soy bean; Walnut; Wheat |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Bahia grass; Barley; Bermuda grass; Johnson grass; Kentucky blue; Kentucky plane (June) grass; Meadow grass; Paspalum grass; Perennial rye grass; Rye grass; Timothy grass |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | German cockroach |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Alternaria alternata; Aspergillus fumigatus; Cladosporium herbarum; Penicillium chrysogenum (formerly Penicillium notatum) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite; House dust - Hollister-Stier |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | House dust; Inhalant panel; Latex |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Eucalyptus; Melaleuca; Olive |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | Common wasp (yellow jacket) venom; Honey bee venom; Paper wasp venom |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Common ragweed; Goosefoot; Lamb’s quarters; Mugwort; Nettle; Plantain - English; Ribwort; Russian thistle; Saltwort (prickly) |
| Immunopathology - Investigation of natural killer cell release from target cells | Blood | Natural killer (NK) cell cytotoxicity; Natural killer (NK) cell degranulation |
| Natural killer (NK) cell cytotoxicity | ||
| Immunopathology - Quantitation of complement proteins | Serum | Total haemolytic complement |
| Complement components C3 and C4 | ||
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Cerebrospinal fluid (CSF) | Immunoglobulin G (IgG) - Kappa |
| Oligoclonal bands | ||
| Serum | Detection and amount of paraproteins | |
| Detection and quantitation of free kappa and free lambda light chains | ||
| Cryofibrinogen; Cryoglobulins | ||
| Eosinophil cationic protein | ||
| Urine | Characterisation of paraproteins; Detection and amount of paraproteins | |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Immunoglobulin subclasses |
| Total immunoglobulin E | ||
| Immunoglobulin subclasses; Total immunoglobulin A; Total immunoglobulin D; Total immunoglobulin G; Total immunoglobulin M | ||
| Immunopathology - Single HLA antigen typing | Blood | HLA-B5701 |
| Immunopathology - Tests of cellular immunity - Lymphocyte function tests | Blood | Lymphocyte function; Proliferation by antigens; Proliferation by mitogens |
| T-lymphocyte, B-lymphocyte and natural killer (TBNK) | ||
| Microbiology - Molecular biology - Microbial genotyping | Plasma | Human immunodeficiency virus type 1 (HIV-1) sequencing for drug resistance |
| Microbiology - Molecular biology - Quantitation of microbial nucleic acids | Cerebrospinal fluid (CSF) | Human immunodeficiency virus (HIV) RNA viral load |
| Plasma | Human immunodeficiency virus (HIV) RNA viral load | |
| Microbiology - Mycobacteriology - Tests for antigen lymphocyte stimulation | Blood | Mycobacterial antigen lymphocyte stimulation |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Serum | Human immunodeficiency virus (HIV) p24 antigen; Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies |
| Serum | Human T-lymphotropic virus type I/II (HTLV-I/II) | |
| Aspergillus spp. total antibody; Avian precipitins (bird fancier's disease); Farmer's lung precipitins | ||
| Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies |
Department of Medical Genomics
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood; Extracted DNA | Apolipoprotein E; Butyrylcholinesterase (BChE); Hereditary haemochromatosis; Nudix hydrolase 15 gene (NUDT15); Thiopurine methyltransferase (TPMT); α1-Antitrypsin |
| Inherited disorders; Nucleic acid analysis for specific variants; Variants in the nuclear genome | ||
| Molecular genetics - DNA extraction | Blood | DNA storage for future analyses; Viable DNA; Viable DNA for sequencing; Viable DNA for sequencing and other molecular assays |
| Blood; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue; Tissues | Viable DNA | |
| Saliva | DNA storage for future analyses; Viable DNA; Viable DNA for sequencing; Viable DNA for sequencing and other molecular assays | |
| Molecular genetics - DNA fragment size analysis | Blood; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue | DNA fragment size determination; Sample identification using microsatellite DNA markers |
| Molecular genetics - DNA sequencing | Extracted DNA | Sequenced DNA by Sanger sequencing |
| Molecular genetics - Detection and characterisation of cell free RNA (cfRNA)/cell free DNA (cfDNA)/cell free TNA (cfTNA)/circulating tumour DNA (ctDNA) in cancer screening and/or cancer genetic testing | Blood; Body fluids; Cerebrospinal fluid (CSF); Plasma | Nucleic acid analysis for specific variants |
| Blood; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue | Copy number variation (CNV); Exon skipping; Gene fusion; Indels; Nucleic acid analysis for specific variants; Single nucleotide variants (SNVs); Solid tumours | |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue | Melanoma; Metastatic colorectal carcinoma; Non-small cell lung cancer and other tumours |
| Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue; Tissues | Non-small cell lung cancer and other tumours; Solid tumours | |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue | Melanoma; Metastatic colorectal carcinoma; Non-small cell lung cancer and other tumours |
| Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue | Exon skipping; Gene fusion; Solid tumours | |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes | Blood; Extracted DNA | Familial hypercholesterolemia; Porphyria; Rare thalassaemias; Variant haemoglobin; α-Thalassaemia; β-Thalassaemia |
| Butyrylcholinesterase (BChE); Familial hypercholesterolemia; Hereditary fructose intolerance; Hereditary haemochromatosis; Inherited disorders; Porphyria; Rare thalassaemias; Variant haemoglobin; Variants in the nuclear genome; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia | ||
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Familial hypercholesterolemia; Porphyria |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Whole exome sequencing studies for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Inherited disorders; Nucleic acid analysis for unknown variants; Variants in the nuclear genome |
| Molecular genetics - Predictive genetic testing - Targeted genes | Blood; Extracted DNA | Huntington's disease |
| Familial hypercholesterolemia; Porphyria | ||
| Familial hypercholesterolemia; Porphyria | ||
| Molecular genetics - RNA extraction | Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen tissue; Tissues | RNA storage for future analyses; Viable RNA; Viable RNA for molecular diagnostics; Viable RNA for sequencing |
| Molecular genetics/Cytogenetics - Bioinformatic analysis | FASTQ files | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
Department of Microbiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-Saccharomyces cerevisiae antibodies (ASCA) |
| Anti-intrinsic factor antibodies (IF) | ||
| Immunopathology - Tests of cellular immunity - Cytokine assays | Serum | Interferon-γ (IFN-γ) |
| Microbiology - Bacteriology - Detection and identification of crystalline material | Synovial fluid | Crystal detection and identification |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Ascitic fluid; Cerebrospinal fluid (CSF); Peritoneal fluid; Synovial fluid | Pathogenic identification and antibiotic susceptibility |
| Aspirates; Bacterial isolates; Biopsy specimens; Blood; Bronchoalveolar lavage; Bronchoalveolar washings; Cerebrospinal fluid (CSF); Enteric swabs; Eye swabs; Faeces; Fine needle aspirates (FNA); Fluids; Gastric aspirate; Gastric biopsy; General swabs; Genital specimens; Genital swabs; Operative specimens; Plasma; Post-operative wounds; Pus; Respiratory specimens; Synovial fluid; Throat swabs; Tissues; Wound swabs | Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Bacterial isolates | Pathogenic identification and antibiotic susceptibility | |
| Blood | Bacteria; Pathogenic microorganisms | |
| Blood; Tissues | Pathogenic identification and antibiotic susceptibility | |
| Pathogenic identification and antibiotic susceptibility | ||
| Cerebrospinal fluid (CSF); Fluids; Human breast milk; Intra-uterine contraceptive device (IUCD); Operative specimens; Respiratory specimens; Synovial fluid; Throat swabs; Urine; Wound swabs | Pathogenic identification and antibiotic susceptibility | |
| Cerebrospinal fluid (CSF); Fluids; Human breast milk; Intra-uterine contraceptive device (IUCD); Operative specimens; Respiratory specimens; Throat swabs; Urine; Wound swabs | Pathogenic identification and antibiotic susceptibility | |
| Faeces; Genital swabs | Pathogenic identification and antibiotic susceptibility | |
| Synovial fluid | Pathogenic identification and antibiotic susceptibility | |
| Urine | Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Pathogenic microorganisms | |
| Streptococcus pneumoniae antigen | ||
| Legionella antigen | ||
| Bacteria; Casts; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Pathogenic microorganisms | ||
| Microbiology - Bacteriology - Detection of pathogenic bacteria for epidemiological infection control surveillance | Axilla swabs; Faeces; Groin swabs; Infection control swabs; Nasal swabs; Rectal swabs; Wounds | Carbapenem resistant Enterobacteriaceae (CRE); Extended spectrum beta-lactamases (ESBL); Metallo-β-lactamase (MBL) carbapenemase; Methicillin resistant Staphylococcus aureus (MRSA); Multi-drug resistant gram negative bacteria (MDR); Vancomycin resistant Enterococci (VRE) |
| Carbapenem resistant Enterobacteriaceae (CRE); Extended spectrum beta-lactamases (ESBL); Metallo-β-lactamase (MBL) carbapenemase; Methicillin resistant Staphylococcus aureus (MRSA); Multi-drug resistant gram negative bacteria (MDR); Vancomycin resistant Enterococci (VRE) | ||
| Microbiology - Environmental investigations and/or infection control (Clinical non-human testing) | Aortic valve; Mitral valve | Organism characterisation for patient management; Pathogenic identification and antibiotic susceptibility |
| Organism characterisation for patient management; Pathogenic identification and antibiotic susceptibility | ||
| Bacterial isolates; Microbial nucleic acids; Non-human clinical isolates | Detection and characterisation of organisms (including identification and typing); Organism characterisation for patient management; Phylogenetic analysis | |
| Blood transfusion bags; Bronchoscopes; Catheter tips; Endoscopes; Gastrointestinal endoscopes; Vascular catheter tips | Bacterial growth - Sterility; Bacterial organism identification - Gram negative multi-drug resistant organisms (MRO); Bacterial organism identification - Methicillin-resistant Staphylococcus aureus (MRSA); Bacterial organism identification - Vancomycin-resistant Enterococcus (VRE); Pathogenic identification and antibiotic susceptibility | |
| Bacterial growth - Sterility; Bacterial organism identification - Gram negative multi-drug resistant organisms (MRO); Bacterial organism identification - Methicillin-resistant Staphylococcus aureus (MRSA); Bacterial organism identification - Vancomycin-resistant Enterococcus (VRE); Pathogenic identification and antibiotic susceptibility | ||
| Microbiology - Molecular biology - Bioinformatic analysis | DNA sequences; RNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Bacterial isolates | Pan-bacterial 16s |
| PorA | ||
| Bacterial isolates; Blood; Sterile site | Enterococcus faecium; Enterococcus faecium ddl gene; Fem gene; Gram negative bacillus IMP-4 gene; MecA gene; Van A/B | |
| Bacterial isolates; Rectal swabs | CarbaR | |
| Blood; Cerebrospinal fluid (CSF) | Neisseria meningitidis | |
| Cervical specimen; Genital swabs; Rectal swabs; Urine; Vaginal swabs | Mycoplasma genitalium | |
| Cervical specimen; Liquid based cytology specimens; Rectal swabs; Throat swabs; Urethral swabs; Urine; Vaginal swabs | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Neisseria gonorrhoeae | ||
| Cervical swabs; Genital swabs; Rectal swabs; Urine; Vaginal swabs | Macrolide resistant Mycoplasma genitalium | |
| Faeces | Campylobacter spp.; Clostridium difficile toxin B; Salmonella spp.; Shigella spp. | |
| Nasopharyngeal swabs | Bordetella pertussis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (fungi) | Blood culture; Isolates | Candida spp.; Cryptococcus gattii; Cryptococcus neoformans |
| Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Respiratory swabs; Sterile site | Pneumocystis jirovecii | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | Aspirates; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Respiratory specimens; Tissues; Urine | Mycobacterium tuberculosis |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Dientamoeba fragilis; Entamoeba histolytica; Giardia lamblia |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Amniotic fluid; Aspirates; Blood; Cerebrospinal fluid (CSF); Serum; Tissues; Urine | Cytomegalovirus (CMV) |
| Amniotic fluid; Blood; Serum; Tissues | Parvovirus B19 | |
| Amniotic fluid; Eye swabs; Fluids; Genital swabs; Tissues | Herpes simplex virus type 1 (HSV1); Herpes simplex virus type 2 (HSV2); Human parechovirus; Varicella zoster virus (VZV) | |
| Blood | Cytomegalovirus (CMV) | |
| Epstein-Barr virus | ||
| Blood; Eye swabs | Adenovirus | |
| Blood; Urine | BK virus | |
| Bronchial washings; Bronchoalveolar lavage; Endotrachael aspirate; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Bronchial washings; Bronchoalveolar lavage; Nasal aspirates/washes; Nasal swabs; Nasopharyngeal aspirate; Sputum; Throat swabs | Adenovirus; Coronavirus; Enterovirus; Human metapneumovirus; Human parechovirus; Influenza A virus H1 - 2009 pandemic strain; Influenza A virus H3N2; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV); Rhinovirus; Varicella zoster virus (VZV) | |
| Bronchoalveolar lavage; Nasopharyngeal and throat swab; Nasopharyngeal aspirate | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Bronchoalveolar lavage; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Throat swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Cerebrospinal fluid (CSF) | Enterovirus; Epstein-Barr virus; Herpes simplex virus type 1 (HSV1); Herpes simplex virus type 2 (HSV2); Human parechovirus; Varicella zoster virus (VZV) | |
| Cerebrospinal fluid (CSF); Respiratory specimens | Enterovirus; Epstein-Barr virus; Herpes simplex virus type 1 (HSV1); Herpes simplex virus type 2 (HSV2); Human parechovirus; Varicella zoster virus (VZV) | |
| Faeces | Adenovirus; Norovirus; Rotavirus | |
| Liquid based cytology specimens | Human papilloma virus (HPV) | |
| Nasal aspirates/washes; Nasal swabs; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal swabs; Nasopharyngeal and throat swab; Nasopharyngeal aspirate | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal swabs; Nasopharyngeal swabs; Oropharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Nasal swabs; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal swabs; Oropharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasopharyngeal aspirate; Throat swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) | |
| Plasma | BK virus | |
| Cytomegalovirus (CMV) | ||
| Epstein-Barr virus | ||
| Serum | Hepatitis B virus (HBV) DNA | |
| Hepatitis C virus (HCV) viral RNA; Hepatitis C virus (HCV) viral load - Qualitative | ||
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids by whole genome sequencing | Bacterial isolates; Microbial nucleic acids | Microbial identification; Resistance; Virulence |
| Microbiology - Molecular biology - Environmental and/or infection control | Bacterial isolates; Microbial nucleic acids; Non-human clinical isolates | Organism characterisation for patient management; Pathogenic identification and antibiotic susceptibility; Phylogenetic analysis |
| Microbiology - Molecular biology - Microbial DNA and/or RNA extraction | Isolates | Viable DNA for sequencing |
| Microbiology - Molecular biology - Microbial DNA and/or RNA sequencing | Extracted DNA; Extracted RNA | Sequenced DNA utilising massively parallel sequencing technologies |
| Microbiology - Molecular biology - Microbial genotyping | Serum | Hepatitis C virus (HCV) RNA genotypes 1-6 |
| Microbiology - Molecular biology - Microbial genotyping by whole genome sequencing studies | DNA | Bacteria |
| Microbiology - Molecular biology - Public health investigation and/or monitoring | Bacterial isolates; Microbial nucleic acids; Non-human clinical isolates | Detection and characterisation of organisms (including identification and typing); Organism characterisation for patient management; Phylogenetic analysis |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Other body fluids; Respiratory specimens; Sputum; Tissues; Urine | Mycobacteria identification |
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Blood; Cerebrospinal fluid (CSF); Ear swabs; Eye swabs; Fluids; Genital swabs; Nasal swabs; Respiratory specimens; Skin swabs; Tissues; Wound swabs | Fungi detection; Fungi identification; Isolation of yeasts and Aspergillus; Yeast detection; Yeasts identification |
| Blood; Cerebrospinal fluid (CSF); Ear swabs; Eye swabs; General swabs; Genital swabs; Nasal swabs; Respiratory specimens; Skin swabs; Tissues; Wound swabs | Fungi detection; Fungi identification; Isolation of yeasts and Aspergillus; Yeast detection; Yeasts identification | |
| Cerebrospinal fluid (CSF); General swabs | Yeast detection | |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Cerebrospinal fluid (CSF); Serum | Cryptococcus spp. |
| Faeces | Clostridioides difficile toxin | |
| Plasma; Serum | Cytomegalovirus (CMV) IgG avidity; Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Epstein-Barr virus nuclear antigen IgG antibody; Epstein-Barr virus viral capsid antigen IgG antibody; Epstein-Barr virus viral capsid antigen IgM antibody; Hepatitis D virus antibody (anti-HDV); Herpes simplex virus type 2 antibody (anti-HSV2) - IgG; Herpes simplex type 1 antibody (anti-HSV1) - IgG; Measles IgG antibody; Measles IgM antibody; Mumps virus IgG antibody; Mycoplasma pneumoniae IgM antibody; Parvovirus B19 IgG antibody; Parvovirus B19 IgM antibody; Rubella IgG antibody; Syphilis Treponema pallidum antibody; Toxoplasma spp. IgG antibody; Toxoplasma spp. IgM antibody; Varicella zoster virus (VZV) IgG antibody | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody | ||
| Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis A virus antibody (anti-HAV) - Total; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis B virus surface antigen (HBs Ag) - Confirmatory; Hepatitis C virus antibody (anti-HCV) | ||
| Serum | Legionella spp. | |
| Amoebae | ||
| Hepatitis E virus (HEV) IgG; Hepatitis E virus (HEV) IgM | ||
| Helicobacter pylori | ||
| Hydatid antibody | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody | ||
| Brucella spp. | ||
| Herpes simplex virus (HSV) IgM | ||
| Hepatitis C virus (HCV) | ||
| Syphilis Treponema pallidum antibody | ||
| Dengue virus | ||
| Streptococcal anti-DNAse B (anti-streptodornase) antibody | ||
| Varicella zoster virus IgM antibody | ||
| Microbiology - Virology - Detection of pathogenic viruses | Faeces | Adenovirus; Rotavirus |
Department of Tissue Pathology and Diagnostic Oncology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Liquid based cytology specimens from cervix | Human papilloma virus cytological examination; Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Cytopathology - Gynaecological (non-cervical) cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Liquid based cytology specimens from cervix | Cytological examination; Review and reporting of gynaecological (non-cervical tissue) cytological samples |
| Anatomical pathology - Cytopathology - Immunocytochemical investigation (on non-paraffin embedded cellular preparations) | Fixed cytological smears | Detection of antigenic targets - Various |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Aspirates; Bronchial lavage; Cerebrospinal fluid (CSF); Other body fluids; Sputum; Tumour tissue; Urine; Washings or brushings from other sites | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of nipple discharge or smears from squamous mucosal sites for the detection of cancerous or precancerous changes | Anus smears; Lip smears; Mouth smears; Nipple discharge; Nose smears; Semen; Skin smears | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin fluorescence in situ hybridisation (FISH) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue; Sentinel node; Smears; Tissue imprint | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Immunohistochemical (immunofluorescence) investigation | Fresh tissue; Frozen tissue | Detection of antigenic targets - Various |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Fixed cytological smears; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen sections of fresh tissue | Detection of antigenic targets - Various |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Formalin-fixed paraffin-embedded (FFPE) tissues | BRAF mutation analysis; EGFR mutation analysis; KRAS mutation analysis; NRAS mutation analysis |
Emergency Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Green Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
IRO Theatre
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood | Calcium - Ionised; Chloride; Creatinine; Glucose; Potassium; Sodium; Total carbon dioxide (TCO2); Urea |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Total carbon dioxide (TCO2); pH |
| Haematology - Full blood examination | Blood | Haematocrit (packed cell volume, PCV); Haemoglobin (Hb) |
Lifehouse (Intensive Care Unit)
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Lifehouse Operating Theatres
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Neonatal Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Neuro Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Respiratory Investigation Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Theatre (Main Hospital Theatres JL)
ISO 15189 (2022)
Human Pathology
Medicare expiry date
08 Dec 2026
Last Activity Date
26 Jul 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2146
Site No.
2139
Print date
29 Nov 2024
END OF SCOPE